PD-1/PD-L1 in disease

被引:109
|
作者
Kuol, Nyanbol [1 ]
Stojanovska, Lily [1 ]
Nurgali, Kulmira [1 ]
Apostolopoulos, Vasso [1 ]
机构
[1] Victoria Univ, Coll Hlth & Biomed, Ctr Chron Dis, POB 14426, Melbourne, Vic 8001, Australia
关键词
autoimmune disease; cancer; neurological disease; PD-1; PD-L1; vaccines; DEATH-LIGAND; 1; CELL LUNG-CANCER; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CD4(+) T-CELLS; PD-L1; EXPRESSION; OPEN-LABEL; BREAST-CANCER; IMMUNOINHIBITORY MOLECULE; CLINICAL-SIGNIFICANCE; POOR-PROGNOSIS;
D O I
10.2217/imt-2017-0120
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aim: Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor signal transduction. PD-L1 and PD-1 blockade using antibodies are in human clinical trials as an alternative cancer treatment modality. Areas covered: We describe the role of PD-1/PD-L1 in disease in the context of autoimmunity, neurological disorders, stroke and cancer. Conclusion: For immunotherapy/vaccines to be successful, the expression of PD-L1/PD-1 on immune cells should be considered, and the combination of checkpoint inhibitors and vaccines may pave the way for successful outcomes to disease.
引用
收藏
页码:149 / 161
页数:13
相关论文
共 50 条
  • [1] PD-1/PD-L1 in cardiovascular disease
    Sun, YunFeng
    Li, Liang
    Wu, YaWei
    Yang, KePing
    CLINICA CHIMICA ACTA, 2020, 505 : 26 - 30
  • [2] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [3] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [4] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [5] PD-1 and PD-L1 prognostic in UTUC
    Stone, Louise
    NATURE REVIEWS UROLOGY, 2017, 14 (09) : 518 - 518
  • [6] PD-1 and PD-L1 prognostic in UTUC
    Louise Stone
    Nature Reviews Urology, 2017, 14 : 518 - 518
  • [7] A snapshot of the PD-1/PD-L1 pathway
    Ghosh, Chinmoy
    Luong, Gary
    Sun, Yue
    JOURNAL OF CANCER, 2021, 12 (09): : 2735 - 2746
  • [8] PD-1 and PD-L1 antibodies for melanoma
    Tsai, Katy K.
    Zarzoso, Ines
    Daud, Adil I.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (11) : 3111 - 3116
  • [9] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
    Annika De Sousa Linhares
    Claire Battin
    Sabrina Jutz
    Judith Leitner
    Christine Hafner
    Joshua Tobias
    Ursula Wiedermann
    Michael Kundi
    Gerhard J. Zlabinger
    Katharina Grabmeier-Pfistershammer
    Peter Steinberger
    Scientific Reports, 9
  • [10] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
    Linhares, Annika De Sousa
    Battin, Claire
    Jutz, Sabrina
    Leitner, Judith
    Hafner, Christine
    Tobias, Joshua
    Wiedermann, Ursula
    Kundi, Michael
    Zlabinger, Gerhard J.
    Grabmeier-Pfistershammer, Katharina
    Steinberger, Peter
    SCIENTIFIC REPORTS, 2019, 9 (1)